Immunogenicity or Human Anti-Mouse Antibodies (HAMA) response is what happens when antibodies derived from xenogeneic sources are administered to humans. This can potentially decrease the effectiveness of immune-treatment through rapid clearance of the therapeutic antibody or immune-conjugate. In some cases, the patient may even develop an allergic sensitivity and be at risk of anaphylactic shock upon any future treatment containing these “foreign” antibodies. Due to this potential risk of immunogenicity and HAMA response, the humanization of antibodies from xenogeneic sources to become safer and more reliable humanized antibody drugs is critical.
Synbio Technologies has developed an integrated antibody humanization and affinity maturation platform based on the advanced phage/yeast display technologies and progressive computer modeling and simulation techniques. Collectively, we have combined methods from bioinformatics and structural biology to optimize our approach toward integrated antibody humanization. Our antibody humanization services include in silico CDR-grafting, computer-aided design and optimization, high-throughput screening of phage-display antibodies, and Biacore surface resonance analysis. With this approach, we are able to provide humanized antibodies with diminished immunogenicity, which have comparable or better specificity, bioactivity, thermos-stability, and productivity than parental antibodies. Subsequent affinity maturation service assures optimal humanized antibody output with an increased binding affinity by at least five-fold.
- Extensive Experience: Our team has practical experience with humanized antibody design, screening, and production to ensure the success of our customers’ project.
- In Silico Design: Effective and reliable antibody modeling and simulating from multiple antibody databases.
- High-Throughput Screening: Phage/yeast display platform designing to enhance the valid antibody yield.
- Guaranteed Affinity: After affinity maturation the final construct’s affinity is improved by at least five-fold.
|Details||Deliverables||Turnaround Time |